Pharvaris to Participate in Upcoming March Investor Conferences

Mar 03, 2022

ZUG, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in three upcoming investor conferences in March:

BioCapital Europe 2022
Format: Live In-Person Presentation
Date/Time: Thursday, March 10, 2022 at 3:00 PM CET (9:00 AM EST)
Location: Amsterdam, Netherlands

Oppenheimer 32nd Annual Healthcare Conference
Format: Webcasted Fireside Chat
Date/Time: Tuesday, March 15, 2022 at 8:00 AM ET
Location: Virtual

SVB Leerink Mountain Meeting
Format: Live In-Person Presentation
Date/Time: Tuesday, March 22, 2022, at 9:30 AM MT (11:30 AM ET)
Location: Jackson Hole, Wyoming

A live audio webcast of the Oppenheimer 32nd Annual Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: A replay will be available on Pharvaris’ website for 30 days following the fireside chat.

About Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit

Maryann Cimino
Director of Corporate Relations

Investor Contact
Sarah McCabe
Stern Investor Relations, Inc.

Media Contact
Maggie Beller
Russo Partners, LLC